Thrombocytosis as a Prognostic Marker in Gastrointestinal Cancers

World Journal of Gastrointestinal Oncology

Volumn 6, Issue 2, 2014, Pages 34-40

  Voutsadakis, Ioannis A ^a  

^a Sault Area Hospitals   (Canada)

Author keywords

Cancer; Gastrointestinal; Platelets; Prognosis; Thrombocytosis

Indexed keywords

EID: 84904167594     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i2.34     Document Type: Article

References (66)

1. 1 Yu M, Cantor AB. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods Mol Biol 2012; 788: 291–303 [PMID: 22130715 DOI: 10.1007/978–1–61779–307–3_20]
2. 2 Psaila B, Lyden D, Roberts I. Megakaryocytes, malignancy and bone marrow vascular niches. J Thromb Haemost 2012; 10: 177–188 [PMID: 22122829 DOI: 10.1111/j.1538–7836.2011.04571.x]
3. 3 Thon JN, Italiano JE. Platelet formation. Semin Hematol 2010; 47: 220-226 [PMID: 20620432 DOI: 10.1053/j.seminhematol.2010.03.005]
4. 4 Bleeker JS, Hogan WJ. Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis 2011; 2011: 536062 [PMID: 22084665 DOI: 10.1155/2011/536062]
5. 5 Ertenli I, Kiraz S, Oztürk MA, Haznedaroğlu Ic, Celik I, Calgüneri M. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003; 23: 49-60 [PMID: 12634936]
6. 6 Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89: 1098-1106 [PMID: 12783124]
7. 7 Stravodimou A, Voutsadakis IA. Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer. Int J Breast Cancer 2013; 2013: 289563 [PMID: 23864954 DOI: 10.1155/2013/289563]
8. 8 Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618 [PMID: 22335738 DOI: 10.1056/NEJMoa1110352]
9. 9 Digklia A, Voutsadakis IA. Pretreatment thrombocytosis in advanced ovarian cancer. (abstract). ECCO Congress, 2013. Available from: URL: http://www.poster-submission.com/board
10. 10 Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-207 [PMID: 10930915]
11. 11 Todenhöfer T, Renninger M, Schwentner C, Stenzl A, Gakis G. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int 2012; 110: E533-E540 [PMID: 22578156 DOI: 10.1111/j.1464-410X.2012.11231.x]
12. 12 Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-2977 [PMID: 1591690]
13. 13 Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L, Hideghéty K. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res 2013; 33: 1725-1729 [PMID: 23564823]
14. 14 Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140 [PMID: 12714883]
15. 15 Paule B, Belot J, Rudant C, Coulombel C, Abbou CC. The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol 2000; 53: 388-390 [PMID: 10889822]
16. 16 Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-2706 [PMID: 10914713]
17. 17 Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311-315 [PMID: 11899364]
18. 18 Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998; 77: 907-912 [PMID: 9528833]
19. 19 Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10: 1115-1120 [PMID: 15069709]
20. 20 Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, Bębenek M, Gamian A. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett 2013; 337: 107-114 [PMID: 23726839 DOI: 10.1016/j.canlet.2013.05.033]
21. 21 Waldner MJ, Foersch S, Neurath MF. Interleukin–6––a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8: 1248-1253 [PMID: 23136553 DOI: 10.7150/ijbs.4614]
22. 22 Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Otsuji E. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011; 31: 67-75 [PMID: 21273582]
23. 23 Matowicka-Karna J, Kamocki Z, Polińska B, Osada J, Kemona H. Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol 2013; 2013: 401623 [PMID: 23554823 DOI: 10.1155/2013/401623]
24. 24 Le Bitoux MA, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol 2008; 130: 1079-1090 [PMID: 18953558 DOI: 10.1007/s00418-008-0527-3]
25. 25 Palazón A, Aragonés J, Morales-Kastresana A, de Landázuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18: 1207-1213 [PMID: 22205687 DOI: 10.1158/1078-0432. CCR-11-1591]
26. 26 Buergy D, Wenz F, Groden C, Brockmann MA. Tumorplatelet interaction in solid tumors. Int J Cancer 2012; 130: 2747-2760 [PMID: 22261860 DOI: 10.1002/ijc.27441]
27. 27 Ho-Tin-Noé B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost 2011; 9 Suppl 1: 56-65 [PMID: 21781242 DOI: 10.1111/j.1538-7836.2011.04317.x]
28. 28 Ho-Tin-Noé B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009; 175: 1699-1708 [PMID: 19729481 DOI: 10.2353/ajpath.2009.090460]
29. 29 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-134 [PMID: 21258396 DOI: 10.1038/nrc3004]
30. 30 Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-174 [PMID: 10705245]
31. 31 Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymallike transition and promotes metastasis. Cancer Cell 2011; 20: 576-590 [PMID: 22094253 DOI: 10.1016/j.ccr.2011.09.009]
32. 32 Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428 [PMID: 19487818 DOI: 10.1172/JCI39104]
33. 33 Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69: 7775-7783 [PMID: 19738039 DOI: 10.1158/0008-5472. CAN-09-2123]
34. 34 Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 2011; 6: e19873 [PMID: 21637343 DOI: 10.1371/journal.pone.0019873]
35. 35 Waldner MJ, Wirtz S, Jefremow A, Warntjen M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S, Neurath MF. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010; 207: 2855-2868 [PMID: 21098094 DOI: 10.1084/jem.20100438]
36. 36 Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741 [PMID: 15110807]
37. 37 Aminian A, Karimian F, Mirsharifi R, Alibakhshi A, Dashti H, Jahangiri Y, Safari S, Ghaderi H, Noaparast M, Hasani SM, Mirsharifi A. Significance of platelet count in esophageal carcinomas. Saudi J Gastroenterol 2011; 17: 134-137 [PMID: 21372352 DOI: 10.4103/1319-3767.77245]
38. 38 Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, Noh SH. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012; 38: 562-567 [PMID: 22592098 DOI: 10.1016/j.ejso.2012.04.009]
39. 39 Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-291 [PMID: 11923136]
40. 40 Wang L, Huang X, Chen Y, Jin X, Li Q, Yi TN. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol 2012; 38: 568-573 [PMID: 22595739 DOI: 10.1016/j.ejso.2012.04.008]
41. 41 Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol 2010; 40: 1147-1153 [PMID: 20647232 DOI: 10.1093/jjco/hyq111]
42. 42 Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005; 189: 278-282 [PMID: 15792750]
43. 43 Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 2004; 51: 847-853 [PMID: 15143932]
44. 44 Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001; 48: 1493-1498 [PMID: 11677994]
45. 45 Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernández-Del Castillo C. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg 2008; 32: 1051-1056 [PMID: 18224462 DOI: 10.1007/s00268-007-9423-6]
46. 46 Sirivatanauksorn Y, Tovikkai C. Comparison of staging systems of hepatocellular carcinoma. HPB Surg 2011; 2011: 818217 [PMID: 21760664 DOI: 10.1155/2011/818217]
47. 47 Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000; 20: 499-506 [PMID: 10841078]
48. 48 Ryu T, Nishimura S, Miura H, Yamada H, Morita H, Miyazaki H, Kitamura S, Miura Y, Saito T. Thrombopoietinproducing hepatocellular carcinoma. Intern Med 2003; 42: 730-734 [PMID: 12924502]
49. 49 Shafford EA, Pritchard J. Extreme thrombocytosis as a diagnostic clue to hepatoblastoma. Arch Dis Child 1993; 69: 171 [PMID: 8024312]
50. 50 Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16: 329-333 [PMID: 9766812]
51. 51 Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013; 58: 1790-1796 [PMID: 23314854 DOI: 10.1007/s10620-012-2527-3]
52. 52 Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2472-2477 [PMID: 15300887]
53. 53 Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer 2013; 44: 293-304 [PMID: 23549858 DOI: 10.1007/s12029-013-9491-9]
54. 54 Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 2012; 59: 1687-1690 [PMID: 22591645 DOI: 10.5754/hge12277]
55. 55 Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol 2012; 106: 887-891 [PMID: 22623286 DOI: 10.1002/jso.23163]
56. 56 Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012; 36: 192-200 [PMID: 22045447 DOI: 10.1007/s00268-011-1329-7]
57. 57 Monreal M, Fernandez-Llamazares J, Piñol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer––a preliminary study. Thromb Haemost 1998; 79: 916-918 [PMID: 9609220]
58. 58 Kawai K, Kitayama J, Tsuno NH, Sunami E, Watanabe T. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis 2013; 28: 527-535 [PMID: 23080345 DOI: 10.1007/s00384-012-1594-4]
59. 59 Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gómez H, Maffuz A, Rojas-Garcia P, Perez-Alvarez C, Rodriguez-Ramirez S, Rodriguez-Antezana E, Ramirez-Ramirez L. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res 2012; 43: 305-311 [PMID: 22727694 DOI: 10.1016/j.arcmed.2012.06.008]
60. 60 Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419 [PMID: 15199089]
61. 61 Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res 2005; 33: 228-235 [PMID: 15790135]
62. 62 Nyasavajjala SM, Runau F, Datta S, Annette H, Shaw AG, Lund JN. Is there a role for pre-operative thrombocytosis in the management of colorectal cancer? Int J Surg 2010; 8: 436-438 [PMID: 20685408 DOI: 10.1016/j.ijsu.2010.05.005]
63. 63 Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501 [PMID: 15485627]
64. 64 Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 2012; 23: 1549-1555 [PMID: 22056973 DOI: 10.1093/annonc/mdr533]
65. 65 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T,Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435]
66. 66 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]